tiprankstipranks
Trending News
More News >
PAION AG (GB:0NF3)
LSE:0NF3

PAION AG (0NF3) Price & Analysis

Compare
0 Followers

0NF3 Stock Chart & Stats

€0.01
-€0.02(-58.33%)
At close: 4:00 PM EST
€0.01
-€0.02(-58.33%)

0NF3 FAQ

What was PAION AG’s price range in the past 12 months?
PAION AG lowest share price was €0.01 and its highest was €0.01 in the past 12 months.
    What is PAION AG’s market cap?
    PAION AG’s market cap is €85.60K.
      When is PAION AG’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were PAION AG’s earnings last quarter?
      Currently, no data Available
      Is PAION AG overvalued?
      According to Wall Street analysts PAION AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does PAION AG pay dividends?
        PAION AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on PAION AG dividends here
          What is PAION AG’s EPS estimate?
          PAION AG’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does PAION AG have?
          PAION AG has 7,133,699 shares outstanding.
            What happened to PAION AG’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of PAION AG?
            Currently, no hedge funds are holding shares in GB:0NF3
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Company Description

              PAION AG

              Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

              PAION AG (0NF3) Earnings & Revenues

              Similar Stocks
              Company
              Price & Change
              Follow
              Epigenomics
              Heidelberg Pharma AG
              APONTIS PHARMA AG
              Vitruvia Medical AG
              Formycon AG
              Popular Stocks